


Covid-19 Treatment Updates Ver. 3

April 30th 2020

NIH Guidelines

- Reviewed April 29th
- No updates found in the areas of:
 - Prophylaxis (PrEP)
 - Critical Care
 - Concomitant Medications



Famotidine

- The newest game changer?
- Retrospective review of 6200 COVID-19 patients on acid suppression
 - Death rate—data not statistically significant, review admittedly “crude”
 - Famotidine 14%
 - Omeprazole 27%
- NY State Northwell Health conducting a study
 - Enrolled 187 patients goal of 1174
 - Renally impaired not eligible
 - Theory is that famotidine inhibits papain like protease which is necessary for viral replication of Coronavirus
 - Dose 180 mg IV
- Researchers kept study secret due to concerns of hoarding and lack of study drug supply
 - Already reports of product shortages

Science and Annals of Internal Medicine reports

Remdesivir Update

- National Institute of Allergy and Infectious Disease
 - Reportedly will be releasing positive news, Fauci alludes as well
 - Conducting a Phase 3 clinical trial Primary study end points have been met
 - N=800 Double blinded, placebo controlled
- Gilead Pharmaceuticals [SIMPLE](#) trial
 - N= 397 No placebo group or blinding noted
 - 5 day course of therapy equivalent to 10 days course. 200mg load, then 100mg daily
 - 5 day 65% recovered by day 14
 - 10 day 54% recover by day 14
 - Death rate 7% in both groups –data not statistically significant (p=0.14)
 - Give within 10 days of symptom onset
 - Early administration 62% discharge by day 14
 - Later admin—49% discharge by day 14
- Lancet publishing a study from Wuhan
 - N=237 randomized, placebo controlled
 - WHO accidentally leaked trial results showed no benefit

ACE/ARB Update

- Meta analysis
 - N=1480
- Statistically significant reduction in illness of ACE/ARB group
 - 44% reduction in severe disease progression
 - 62% reduction in odds of death
- 19% reduction in hospitalization, not statistically significant
- <https://doi.org/10.1101/2020.04.23.20076661>

MYTH:

CONFIRMED

PLAUSIBLE

BUSTED

BCG Vaccination Update

- RIP BCG vaccination theory
- IF YOU RECALL:
 - Initial report from April 10, 2020
 - Data from 98 countries with nationalized BCG vaccination programs analyzed
 - COVID-19 cases and deaths appear to be lower in these countries at first review
- WHAT THAT INITIAL THEORY WAS MISSING:
 - Researchers figured in COVID -19 testing in these areas
 - The protective trend vanished
 - No statistically significant data was correlated
- When we actively look for COVID -19 it seems you find it regardless of BCG vaccination.
- <https://doi.org/10.1101/2020.04.18.20071142>

